A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.
Myeloproliferative Neoplasms
DRUG: INCB160058
Number of participants with Dose Limiting Toxicities (DLTs), Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol., Up to 28 days|Number of participants with Treatment-emergent Adverse Events (TEAEs), Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug., Up to 2 years and 30 days|Number of participants with TEAEs leading to dose modification or discontinuation, Number of participants with TEAEs leading to dose modification or discontinuation., Up to 2 years and 30 days
INCB160058 pharmacokinetic (PK) in Plasma, INCB160058 concentration in plasma., Up to Day 57|For participants with MF: Response using the revised IWG-MRT and ELN response criteria for MF, Defined as the percentage of participants with Response using the revised International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) response criteria., Week 12 and 24 and then every 24 weeks up to 2 years|For participants with MF: Percentage of participants achieving spleen volume reduction as defined in the protocol, Defined as percentage of participants with a protocol defined Spleen Volume Reduction., Week 12 and Week 24|For participants with PV: Response using revised IWG-MRT and ELN response criteria for PV, Defined as the percentage of participants with Response using the revised International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) response criteria., Week 12 and 24 and then every 24 weeks up to 2 years|For participants with ET: Response using revised IWG-MRT and ELN response criteria for ET, Defined as the percentage of participants with Response using the revised International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) response criteria., Week 12 and 24 and then every 24 weeks up to 2 years|For all participants: Percentage of participants achieving ≥ 50% reduction from baseline of total symptom score (TSS), Defined as the percentage of participants achieving ≥ 50% reduction from baseline of TSS., Week 24|For all participants: Symptom improvement in TSS at Weeks 12 and 24 relative to baseline as measured by the Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF) TSS., Defined as the proportion of participants who achieve a protocol defined reduction in Total Symptomatic Score (TSS) relative to baseline as measured by the MPN-SAF TSS., Week 12 and Week 24
This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.